Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Vaccine Taskforce’s Clive Dix: IP Is A Distraction, We Need To Vaccinate The World As Fast As Possible

UK Should Make Decision On Dose Sharing Now

Executive Summary

Clive Dix, who recently stepped down as chair of the UK Vaccine Taskforce, shares with Pink Sheet his views on its success, why AstraZeneca has been unfairly criticized, how the UK should now share its doses with other countries, and the exciting future of vaccine technology.

You may also be interested in...



Your Annual COVID-19 Vaccine Booster Could Be A Pill Or A Spray

A COVID-19 vaccine in a pill being developed by Vaxart and a nasal spray from Altimmune could offer convenience and maybe even superior immunity compared to injections.

Sanofi Partnership On Oral IL-17 Could Be Turning Point For C4XD

The UK drug discovery specialist has made slow progress until now, but the Sanofi deal could yield a challenger in the competitive psoriasis field.

Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit

The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel